Cognitive changes mediated by adenosine receptor blockade in a resveratrol-treated atherosclerosis-prone lupus mouse model

Lora J Kasselman; Heather A Renna; Iryna Voloshyna; Aaron Pinkhasov; Irving H Gomolin; Isaac Teboul; Joshua De Leon; Steven E Carsons; Allison B Reiss

doi:10.1016/j.jtcme.2022.01.006

Cognitive changes mediated by adenosine receptor blockade in a resveratrol-treated atherosclerosis-prone lupus mouse model

J Tradit Complement Med. 2022 Feb 1;12(5):447-454. doi: 10.1016/j.jtcme.2022.01.006. eCollection 2022 Sep.

Authors

Lora J Kasselman¹, Heather A Renna², Iryna Voloshyna², Aaron Pinkhasov², Irving H Gomolin², Isaac Teboul², Joshua De Leon², Steven E Carsons², Allison B Reiss²

Affiliations

¹ NYU Long Island School of Medicine, Foundations of Medicine, Mineola, NY, USA.
² NYU Winthrop Hospital, Winthrop Research Institute, Department of Medicine, Mineola, NY, USA.

Abstract

Background and aim: Resveratrol is a bioactive molecule used in dietary supplements and herbal medicines and consumed worldwide. Prior work showed that resveratrol's anti-atherogenic properties are mediated in part through the adenosine A2A receptor. The present study explores the potential contribution of adenosine A2A receptor activation to neuroprotective action of resveratrol on cognitive deficits in a model of atherosclerosis-prone systemic lupus erythematosus.

Experimental procedure: Using behavioral analysis (open field, static rod, novel object recognition) and QRT-PCR, this study measured working memory, anxiety, motor coordination, and expression of mRNA in the brain.

Results and conclusion: Data indicate that resveratrol increases working memory, on average but not statistically, and shows a trend towards improved motor coordination (p = 0.07) in atherosclerosis-prone lupus mice. Additionally, resveratrol tends to increase mRNA levels of SIRT1, decrease vascular endothelial growth factor and CX3CL1 mRNA in the hippocampus. Istradefylline, an adenosine A2A receptor antagonist, antagonizes the effects of resveratrol on working memory (p = 0.04) and the expression of SIRT1 (p = 0.03), vascular endothelial growth factor (p = 0.04), and CX3CL1 (p = 0.03) in the hippocampus.This study demonstrates that resveratrol could potentially be a therapeutic candidate in the modulation of cognitive dysfunction in neuropsychiatric lupus, especially motor incoordination. Further human studies, as well as optimization of resveratrol administration, could confirm whether resveratrol may be an additional resource available to reduce the burden of cognitive impairment associated with lupus. Additionally, further studies need to address the role of A2A blockade in cognitive function among the autoimmune population.

Section: 3. Dietary therapy/nutrients supplements.

Taxonomy classification by evise: autoimmunity, inflammation, neurology.

Keywords: Cardiovascular; Cognition; Neurolupus; Nutraceutical; Systemic lupus erythematosus.